Perlman David C, Jordan Ashly E, McKnight Courtney, Young Christopher, Delucchi Kevin L, Sorensen James L, Des Jarlais Don C, Masson Carmen L
a Chemical Dependency Institute, Mount Sinai Beth Israel , New York , New York , USA.
J Addict Dis. 2014;33(4):322-31. doi: 10.1080/10550887.2014.969623.
Drug users are at high risk of viral Hepatitis A, B, and C. The prevalence of Hepatitis A, Hepatitis B, and Hepatitis C, associated factors, and vaccine seroconversion among drug treatment program participants in a randomized controlled trial of hepatitis care coordination were examined. Of 489 participants, 44 and 47% required Hepatitis A/Hepatitis B vaccinations, respectively; 59% were Hepatitis C positive requiring linkage to care. Factors associated with serologic statuses, and vaccine seroconversion are reported; implications for strategies in drug treatment settings are discussed. Results suggest generalizable strategies for drug treatment programs to expand viral hepatitis screening, prevention, vaccination, and linkage to care.
吸毒者感染甲型、乙型和丙型病毒性肝炎的风险很高。在一项关于肝炎护理协调的随机对照试验中，对药物治疗项目参与者中甲型肝炎、乙型肝炎和丙型肝炎的患病率、相关因素以及疫苗血清转化率进行了研究。在489名参与者中，分别有44%和47%的人需要接种甲型肝炎/乙型肝炎疫苗；59%的丙型肝炎检测呈阳性，需要接受护理。报告了与血清学状态和疫苗血清转化率相关的因素；讨论了对药物治疗环境中策略的影响。结果表明，药物治疗项目可采用通用策略来扩大病毒性肝炎筛查、预防、疫苗接种及护理服务。
